Sumit R. Kumar, MD, MPA

#militarymedicine #army #cardiology #cardiacCT

How should we evaluate chest pain in deployed military settings? Our new study in Military Medicine describes the role of coronary CT angiography in a combat environment—where diagnostic certainty matters and resources are limited. 🔗 academic.oup.com/milmed/advance… #CardioTwitter

We are thrilled to announce our incoming Cardiovascular Disease fellows for July 2026. Welcome to the team! 💚🫀🩺 #Cardiology #Fellowship #MatchDay

We’re excited to share that Dr. Thomas Truglio will be continuing on the 4-year CVD-CCEP track and will join our EP fellowship program in 2026. Congratulations, Tom! 🎉 #cardiotwitter #Cardiology #EPFellowship

The Interventional section is pleased to announce a successful match for the 2026/27 training year! Dr. Roberto Herrera will be staying, and he will be joined by Dr. Scott Tully, a graduate of the DHMC internal medicine program. #SCAI #Match2026 #InterventionalCardiology

Despite Class I guideline indications, most patients with severe AR remain untreated. This #JACC review outlines advances in Dx, surgical refinements, & emerging transcatheter options to bridge this gap. jacc.org/doi/10.1016/j.… #TCT2025 #vhdAR @aakriti_15 @ShubhaPawar @mori_md

Throwback Thursday to an amazing evening at Putnam’s Vineyard 🍇 Welcoming our new cardiology fellows and their partners with good vibes, great company, and a beautiful setting. Excited for the journey ahead! ❤️ #ACCFIT

Experts review the effects of exercise on the heart, the approach to common clinical scenarios in #SportsCardio, & the importance of a patient/athlete-centered, SDM approach in the care provided to athletes. 👇 More: bit.ly/3ZyCaAa #ACCAthleticHeart #JACC @JACCJournals

The vast majority of patients with #CHD have Lp(a) levels far below what is considered a typical risk-enhancing threshold, suggesting that the attributable risk from Lp(a) is more complex than previously perceived. jacc.org/doi/10.1016/j.… #JACC #ASCVD #Lipids

Honored to be promoted to Major in the NY Army National Guard! As President Teddy Roosevelt said: "Do what you can, with what you have, where you are." #NYARNG #CitizenSoldier West Lebanon National Guard Soldier Receives New Rank, New Responsibilities dmna-ny.meritpages.com/stories/West-L…

This State-of-the-Art review article focuses on the complications, their prevention, and treatment following transcatheter aortic valve implantation, mitral transcatheter edge-to-edge repair, and transcatheter mitral valve replacement. eurointervention.pcronline.com/article/manage…

Created a centralized Google Sheet summarizing the late-breaking presentations from #ACC2025 — includes article links and key takeaways. Stay informed and ahead! 📄 Link: docs.google.com/spreadsheets/d… 📚 #CardioTwitter #MedTwitter #ACC2025

TIMI Flow: A Key Indicator of Coronary Perfusion TIMI (Thrombolysis in Myocardial Infarction) flow grading is a crucial angiographic tool to assess blood flow in coronary arteries, particularly after an intervention like PCI. 🔹 TIMI 0 (No Flow) – Complete occlusion; no antegrade flow beyond the blockage. 🔹 TIMI 1 (Penetration without Perfusion) – Minimal flow beyond the occlusion but without adequate distal vessel opacification. 🔹 TIMI 2 (Partial Flow) – Delayed but complete filling of the distal vessel; flow is slower than normal. 🔹 TIMI 3 (Normal Flow) – Full, brisk perfusion with normal distal vessel filling, comparable to a non-diseased artery. TIMI 3 flow is the gold standard for successful reperfusion in PCI, improving outcomes in STEMI and other coronary syndromes. #Cardiology #TIMIFlow #CathLab

BHF PROTECT-TAVI: CEP Device Shows No Effect on Stroke Risk After TAVI - American College of Cardiology #ACC25 acc.org/Latest-in-Card…

First day at #ACC25, here are the results of 10 trials presented today. I counted 3 NEJM, 1 Lancet, and 1 JAMA. WARRIOR: Intensive medical therapy did not reduce major CV events at five years in women with suspected INOCA. STRIDE: Semaglutide improved walking distance, symptoms, and quality of life in PAD with diabetes. API-CAT: Low-dose apixaban was noninferior to full-dose for preventing VTE recurrence in cancer patients. RIVAWAR: Rivaroxaban was as effective and safe as warfarin for post-MI LV thrombus resolution at three months. FARES-II: Four-factor PCC was superior to frozen plasma for bleeding control in cardiac surgery. REVERSE-IT: Bentracimab reversed ticagrelor’s antiplatelet effects in urgent surgery or major bleeding. HOST-BR: Three-month DAPT reduced adverse events without more bleeding vs. one-month in high-bleeding-risk patients post-stent. SOUL: Oral semaglutide reduced MACE by 14% over four years with no safety concerns. ADVANCE-HTN: Lorundrostat significantly lowered systolic BP at 12 weeks in uncontrolled hypertension. DAPA-TAVI: Dapagliflozin reduced mortality and heart failure worsening post-TAVI vs. standard care.

#ACC25 #DAPATAVI

Dapagliflozin in Patients Undergoing Transcatheter Aortic-Valve Implantation | New England Journal of Medicine nejm.org/doi/full/10.10… #ACC25

Deep Learning Electrocardiogram Model for Risk Stratification of Coronary Revascularization Need in the Emergency Department academic.oup.com/eurheartj/arti… #ACC25